FDA Ebola Therapeutics Fellowship
*Applications will be reviewed on a rolling-basis.
A research opportunity is currently available in the Office of Pharmaceutical Quality / Office of Biotechnology Products at the Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA) in Silver Spring, Maryland.
Ebola virus (EBOV) causes severe hemorrhagic fever in humans resulting in high mortality rates ranging 50-90%. The need for high containment laboratories where EBOV can be handled has been a major roadblock for understanding the pathogenesis of EBOV as GLP studies under BSL-4 containment is challenging, expensive, and space constraints can significantly delay studies. In these studies we will develop a BSL-2 lethal infection mouse model system that can be used to screen and compare the potency of therapeutic products.
Under the guidance of a mentor, the participant will learn how to establish and characterize an animal model of infection (both in vivo and in vitro) and how to use it to test for antibody dependent enhancement (ADE). S/he will gain understanding about the uses of animal models in the regulatory arena and develop research skills in a laboratory environment.
This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the Silver Spring, Maryland, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.
Qualifications
The qualified candidate should be currently pursuing or have received a doctoral degree in one of the relevant fields. Degree must have been received within five years of the appointment start date.
If you have questions, send an email to ORISE.FDA.CDER@orau.org. Please include the reference code for this opportunity (FDA-CDER-2020-0533) in your email.